Moberg Pharma AB (publ) (MOB) Q1 2021 Earnings Call

Investor webinar replay

Replay transcript excerpt

Hello and welcome to the Moverd Pharma Q1 report. Throughout the call, all participants will be in lithium-aminoid, and afterwards, there will be a question or answer session. Just to remind you, this content will be in record. Today, I am pleased to present CEO Anna Jung. Please go ahead with your meeting. Thank you. Hi, my name is Anna Jung, and I'm the CEO of Moverd Pharma. I also have our great CEO of Finance, Mark Everidge, on the call today. we're happy to present the Q1 report, and you'll find the report on our website, and there you'll also have a PowerPoint presentation, and that's the presentation that I will be placing this teleconferencing on. I'll start on page 3 in that presentation, with an overall. We're a Swedish pharmaceutical company that makes products from a variety of known substances. which reduces time to market and development risk compared to traditional drug development. And our lead program is month 15 in Ultima Corpus, and there we see a global sales potential of $250 to $500 million annually. We recently finalized two large phase 3 trials on more than 800 patients. and we left Canada on point in these trials and have sufficiently satisfied for registration in the EU and we're targeting such a planning during this autumn. Based on average processing times of one and a half years, we expect approval early 2023 and following the launch by the end of 2023. And we're not doing it all by ourselves, we do have partnerships in place for I would say all the major markets except Europe. So perhaps the two most important ones are here, where we have Bayer as a partner, the world leader in MCC anti-fungal treatment, which is a brand channel. And also I want to highlight Taishu, Japan. And in total, our partnership is a milestone of $20 million in ad...